SequelSEC

Medpace Holdings, Inc. MEDP

Services-Commercial Physical & Biological Research · CIK 0001668397 · Fiscal year ends 1231

Revenue
$2.53B
Fiscal year ended 2025-12-31
Operating income
$534.94M
Fiscal year ended 2025-12-31
Free cash flow
$681.87M
Fiscal year ended 2025-12-31

Medpace Holdings, Inc. (MEDP) reported revenue of $2.53B and net income of $451.12M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Medpace Holdings, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Commercial Physical & Biological Research.

Income

Medpace Holdings, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$2.53B$2.11B$1.89B$1.46B$1.14B$925.92M$860.97M$704.59M$436.15M$421.58M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income$534.94M$446.87M$336.82M$278.70M$198.62M$167.04M$127.26M$101.05M$64.86M$52.49M
Net income$451.12M$404.39M$282.81M$245.37M$181.85M$145.38M$100.44M$73.18M$39.12M$13.42M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 29.53Mshares 32.01Mshares 31.84Mshares 33.67Mshares 37.70Mshares 37.71Mshares 37.58Mshares 36.91Mshares 39.84Mshares 36.33M
Pretax income$542.38M$475.92M$335.68M$282.86M$201.85M$168.53M$124.83M$93.95M$56.94M$21.96M
Income tax expense$91.25M$71.54M$52.87M$37.49M$20.00M$23.15M$24.39M$20.77M$17.82M$8.53M
Diluted EPS$15.28$12.63$8.88$7.28$4.81$3.84$2.67$1.97$0.98$0.37
Selling, general & administrative$197.56M$180.18M$161.35M$131.40M$108.42M$92.16M$95.24M$75.68M$63.36M$61.51M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Medpace Holdings, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$497.05M$669.44M$245.45M$28.26M$461.30M$277.77M$131.92M$23.28M$26.48M$37.10M
Total assets$1.98B$2.10B$1.66B$1.35B$1.66B$1.39B$1.14B$967.93M$950.72M$979.10M
Current assets$989.62M$1.03B$593.83M$333.96M$690.91M$473.65M$317.03M$178.11M$129.97M$133.25M
Total liabilities$1.52B$1.28B$1.10B$966.11M$707.01M$584.90M$416.79M$378.23M$447.19M$368.40M
Current liabilities$1.34B$1.10B$925.13M$803.47M$557.22M$440.11M$343.00M$257.03M$192.71M$168.60M
Total equity incl. NCI$459.07M$825.54M$558.95M$386.39M$952.93M$805.78M$726.28M$598.86M$509.26M$610.71M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$402.08M$296.44M$298.40M$253.40M$186.43M$160.96M$155.66M$133.45M$83.08M$79.77M
Goodwill$662.40M$662.40M$662.40M$662.40M$662.40M$662.40M$662.40M$660.98M$660.98M$660.98M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$79.72M$205.11M$151.27M
Accounts payable$28.14M$32.53M$31.87M$33.07M$25.68M$26.55M$22.40M$16.74M$16.67M$10.91M

Cash flow

Medpace Holdings, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow$713.22M$608.82M$433.37M$388.05M$263.33M$258.68M$201.87M$156.58M$97.38M$91.73M
Capital expenditures$31.36M$36.55M$36.65M$36.88M$28.27M$31.34M$17.91M$16.02M$11.72M$13.54M
Investing cash flow-$31.14M-$28.31M-$34.63M-$38.74M-$31.36M-$31.21M-$19.14M-$16.97M-$12.24M-$13.42M
Financing cash flow-$860.39M-$154.01M-$182.64M-$775.78M-$44.45M-$82.28M-$73.92M-$141.58M-$97.83M-$58.01M
Net change in cash-$172.39M$423.99M$217.18M-$433.04M$183.54M$145.85M$108.64M-$3.21M-$10.92M$19.67M
Stock-based compensation$34.79M$25.51M$20.52M$21.41M$14.47M$13.78M$20.74M$6.50M$4.46M$9.82M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$917.39M$169.87M$144.02M$847.85M$62.10M$98.27M$0$0$155.58M$0
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Medpace Holdings, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow$681.87M$572.27M$396.73M$351.17M$235.06M$227.34M$183.96M$140.56M$85.66M$78.20M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin21.1%21.2%17.9%19.1%17.4%18.0%14.8%14.3%14.9%12.5%
FCF margin26.9%27.1%21.0%24.1%20.6%24.6%21.4%19.9%19.6%18.5%
SBC / revenue1.4%1.2%1.1%1.5%1.3%1.5%2.4%0.9%1.0%2.3%
Current ratio0.74x0.93x0.64x0.42x1.24x1.08x0.92x0.69x0.67x0.79x
Revenue YoY growth20.0%11.8%29.2%27.8%23.4%7.5%22.2%61.5%3.5%Unavailable
Net margin17.8%19.2%15.0%16.8%15.9%15.7%11.7%10.4%9.0%3.2%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue1.2%1.7%1.9%2.5%2.5%3.4%2.1%2.3%2.7%3.2%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate16.8%15.0%15.8%13.3%9.9%13.7%19.5%22.1%31.3%38.9%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MEDP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-23View SEC filing
10-Q · Filed 2026-04-23View SEC filing
10-K · Filed 2026-02-10View SEC filing
10-Q · Filed 2025-10-23View SEC filing
10-Q · Filed 2025-07-22View SEC filing
10-Q · Filed 2025-04-22View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2018-12-31

Difference 9153000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2017-12-31

Difference 5730000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.